INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023PRNewsWire • 04/12/23
Inovio Pharmaceuticals, Inc. (INO) Oppenheimer 33rd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/13/23
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/02/23
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical HighlightsPRNewsWire • 03/01/23
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory PapillomatosisPRNewsWire • 02/16/23
INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023PRNewsWire • 02/15/23
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)PRNewsWire • 02/02/23
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine CandidatesPRNewsWire • 01/31/23
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22